Shenzhen Salubris Pharmaceuticals Statistics

Total Valuation

Shenzhen Salubris Pharmaceuticals has a market cap or net worth of CNY 38.04 billion. The enterprise value is 35.97 billion.

Market Cap	38.04B
Enterprise Value	35.97B

Important Dates

The next estimated earnings date is Friday, October 25, 2024.

Earnings Date	Oct 25, 2024
Ex-Dividend Date	Jun 19, 2024

Share Statistics

Shenzhen Salubris Pharmaceuticals has 1.09 billion shares outstanding. The number of shares has increased by 0.75% in one year.

Shares Outstanding	1.09B
Shares Change (YoY)	+0.75%
Shares Change (QoQ)	-0.47%
Owned by Insiders (%)	0.03%
Owned by Institutions (%)	15.32%
Float	412.45M

Valuation Ratios

The trailing PE ratio is 65.84 and the forward PE ratio is 55.70.

PE Ratio	65.84
Forward PE	55.70
PS Ratio	10.37
PB Ratio	4.86
P/FCF Ratio	131.42
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 38.96, with an EV/FCF ratio of 124.24.

EV / Earnings	61.32
EV / Sales	9.66
EV / EBITDA	38.96
EV / EBIT	64.90
EV / FCF	124.24

Financial Position

The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.00.

Current Ratio	2.70
Quick Ratio	2.28
Debt / Equity	0.00
Debt / EBITDA	0.03
Debt / FCF	0.10
Interest Coverage	33.85

Financial Efficiency

Return on equity (ROE) is 7.52% and return on invested capital (ROIC) is 4.35%.

Return on Equity (ROE)	7.52%
Return on Assets (ROA)	3.62%
Return on Capital (ROIC)	4.35%
Revenue Per Employee	1.06M
Profits Per Employee	166,771
Employee Count	3,517
Asset Turnover	0.39
Inventory Turnover	2.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +19.64% in the last 52 weeks. The beta is 0.67, so Shenzhen Salubris Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.67
52-Week Price Change	+19.64%
50-Day Moving Average	30.35
200-Day Moving Average	29.36
Relative Strength Index (RSI)	73.64
Average Volume (20 Days)	6,738,340

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Shenzhen Salubris Pharmaceuticals had revenue of CNY 3.72 billion and earned 586.53 million in profits. Earnings per share was 0.53.

Revenue	3.72B
Gross Profit	2.59B
Operating Income	554.15M
Pretax Income	647.05M
Net Income	586.53M
EBITDA	906.42M
EBIT	554.15M
Earnings Per Share (EPS)	0.53

Full Income Statement

Balance Sheet

The company has 2.14 billion in cash and 28.16 million in debt, giving a net cash position of 2.12 billion or 1.94 per share.

Cash & Cash Equivalents	2.14B
Total Debt	28.16M
Net Cash	2.12B
Net Cash Per Share	1.94
Equity (Book Value)	7.87B
Book Value Per Share	7.18
Working Capital	2.09B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.02 billion and capital expenditures -729.55 million, giving a free cash flow of 289.49 million.

Operating Cash Flow	1.02B
Capital Expenditures	-729.55M
Free Cash Flow	289.49M
FCF Per Share	0.27

Full Cash Flow Statement

Margins

Gross margin is 69.60%, with operating and profit margins of 14.88% and 15.75%.

Gross Margin	69.60%
Operating Margin	14.88%
Pretax Margin	17.38%
Profit Margin	15.75%
EBITDA Margin	24.34%
EBIT Margin	14.88%
FCF Margin	7.77%

Dividends & Yields

This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 1.39%.

Dividend Per Share	0.50
Dividend Yield	1.39%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	39.03%
Buyback Yield	-0.75%
Shareholder Yield	0.64%
Earnings Yield	1.52%
FCF Yield	0.76%

Dividend Details

Stock Splits

The last stock split was on April 24, 2015. It was a forward split with a ratio of 1.6.

Last Split Date	Apr 24, 2015
Split Type	Forward
Split Ratio	1.6

Scores

Shenzhen Salubris Pharmaceuticals has an Altman Z-Score of 12.61.

Altman Z-Score	12.61
Piotroski F-Score	n/a